Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163851 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01163851 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 25 participants.
The verdict
NCT01163851, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin. PF-04950615 (RN316) is an investigational drug that is currently being studies as a cholesterol lowering therapy.
Interventions
- BIOLOGICAL 4 mg/kg
- BIOLOGICAL 0.5 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163851
The ClinicalTrials.gov registry entry for NCT01163851 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 4 mg/kg is the first listed.
NCT01163851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163851 about?
NCT01163851 is a clinical study titled "Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin". The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin. PF-04950615 (RN316) is an investigational drug that is currently being studies as a cholesterol lowering therapy.
What is the current status of trial NCT01163851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2010-07. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01163851?
The interventions under investigation include: 4 mg/kg (BIOLOGICAL), 0.5 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT01163851?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.